Othman Al-Sawaf, MD, physician, the University Hospital of Cologne, discusses the 5-year follow up data from the phase 3 CLL14 trial (NCT02242942) in patients with previously untreated chronic lymphocytic leukemia (CLL) with preexisting conditions.

The open-label, multicenter, randomized study evaluated the efficacy and safety of obinutuzumab (Gazyva) and venetoclax (Venclexta) vs obinutuzumab plus chlorambucil in this patient population.

The 5-year progression-free survival (PFS) rate was 62.6% for patients who received obinutuzumab and venetoclax, compared with 27% in patients administered obinutuzumab plus chlorambucil, Al-Sawaf explains.

Though treatment consisted of only 12 cycles, a majority of the patients remained in remission for more than 4 years after treatment completion, highlighting that a fixed-duration approach is effective in these patients, Al-Sawaf concludes.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


European Hematology Association Congress

Othman Al-Sawaf, MD, discusses the 5-year follow up data from the phase 3 CLL14 trial (NCT02242942) in patients with previously untreated chronic lymphocytic leukemia (CLL) with preexisting conditions.


Dr. Al-Sawaf on the 5-Year Results of the CLL14 Trial in CLL